STMicroelectronics NV (0INB) Receives a Buy from Kepler Capital
In a report released on April 23, Sebastien Sztabowicz from Kepler Capital maintained a Buy rating on STMicroelectronics NV (0INB – Research Report), with a price target of €31.00. The company's shares closed last Thursday at €20.38.
Stay Ahead of the Market:
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Sztabowicz covers the Technology sector, focusing on stocks such as Infineon Technologies AG, Adyen, and ams-OSRAM. According to TipRanks, Sztabowicz has an average return of -7.0% and a 38.93% success rate on recommended stocks.
In addition to Kepler Capital , STMicroelectronics NV also received a Buy from Deutsche Bank 's Nicolas Herms in a report issued yesterday. However, on April 24, Morgan Stanley maintained a Hold rating on STMicroelectronics NV (LSE: 0INB).
0INB market cap is currently €18.16B and has a P/E ratio of 18.74.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $42.00. The company's shares closed last Friday at $29.09. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Matteis is a 3-star analyst with an average return of 1.2% and a 41.20% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Neurocrine, and uniQure. In addition to Stifel Nicolaus, Alkermes also received a Buy from UBS's Ashwani Verma in a report issued on June 17. However, on June 10, RBC Capital maintained a Hold rating on Alkermes (NASDAQ: ALKS).
Business Insider
2 hours ago
- Business Insider
Ventyx Biosciences (VTYX) Gets a Hold from Stifel Nicolaus
In a report released today, from Stifel Nicolaus maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report), with a price target of $2.00. The company's shares closed last Friday at $2.26. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In addition to Stifel Nicolaus, Ventyx Biosciences also received a Hold from Morgan Stanley's Vikram Purohit in a report issued on June 17. However, on June 18, Wells Fargo maintained a Buy rating on Ventyx Biosciences (NASDAQ: VTYX). VTYX market cap is currently $160.8M and has a P/E ratio of -1.29.
Business Insider
2 hours ago
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)
In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), with a price target of $52.00. The company's shares closed last Friday at $16.86. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Travere Therapeutics, and Viridian Therapeutics. According to TipRanks, Thompson CFA has an average return of -3.4% and a 43.20% success rate on recommended stocks. Dianthus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $46.75, which is a 177.37% upside from current levels. In a report released on June 18, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target. The company has a one-year high of $32.27 and a one-year low of $13.37. Currently, Dianthus Therapeutics has an average volume of 319.1K.
